SLN Silence Therapeutics (SLN) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001479615
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
42
13F, latest reported quarter
Silence Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Silence Therapeutics plc in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
no insider purchases or sales on record
0 transactions on record
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
42 funds bought in last quarter
below 56% of Pharma & Biotech
Revenue
-98.7% year over year
below 91% of Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
6.7% of the float short (float per yahoo 2026-10-26) · 3.1 days to cover · settled 2026-09-30
below 67% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch SLN
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+172.8%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns SLN: institutional holders (13F)
13F holdings, latest reported quarter
3,311,438 sh
$36.4M
3,033,560 sh
$33.3M
2,693,462 sh
$29.6M
2,164,777 sh
$23.8M
1,329,625 sh
$14.6M
Congress trades in SLN
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
SLN planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
SLN mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
ALGER SMALL CAP GROWTH FUND
$1.1M position · as of 2026-07-31
0.5%
ALGER SMALL CAP GROWTH INSTITUTIONAL FUND
$433.2K position · as of 2026-07-31
0.5%
Fidelity Advisor Biotechnology Fund
$5.1M position · as of 2026-07-31
0.2%
Invesco Nasdaq Biotechnology ETF
$17.1K position · as of 2026-05-31
0.0%
iShares Biotechnology ETF
$2.0M position · as of 2026-06-30
0.0%
Steward Values Enhanced International Fund
$60.8K position · as of 2026-07-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
5 registered trials, 1 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
2
Phase 1
0 active
1
Phase 2
0 active
1
Early Phase 1
0 active
1
Multi-phase
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 42 funds added last quarter. Each figure is a federal filing, dated the day it went public.
SLN financials
Revenue growth
-98.7%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$615.0K
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM SLN
| FY Dec 2025 | $559.0K |
| FY Dec 2024 | $43.3M |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $0 |
| Mar 2026 | $422.0K |
| Dec 2025 | $34.0K |
| Sep 2025 | $159.0K |
| Jun 2025 | $224.0K |
| Mar 2025 | $142.0K |
| Dec 2024 | $25.3M |
| Sep 2024 | $1.5M |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Net margin, TTM SLN
| FY Dec 2025 | n/a |
| FY Dec 2024 | -104.7% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | -3,544% |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | +48.6% |
| Sep 2024 | -2,373% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$42.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM SLN
| FY Dec 2025 | -$62.3M |
| FY Dec 2024 | -$67.9M |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $1.5M |
| Mar 2026 | -$15.6M |
| Dec 2025 | -$17.3M |
| Sep 2025 | -$10.9M |
| Jun 2025 | -$21.8M |
| Mar 2025 | -$12.3M |
| Dec 2024 | -$27.5M |
| Sep 2024 | -$25.7M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity SLN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt SLN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-90.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity SLN
| FY Dec 2025 | -90.3% |
| FY Dec 2024 | -58.1% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -90.4% |
| Mar 2026 | -92.6% |
| Dec 2025 | -90.3% |
| Sep 2025 | -64.3% |
| Jun 2025 | -66.9% |
| Mar 2025 | -53.1% |
| Dec 2024 | -58.1% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-44.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets SLN
| FY Dec 2025 | -53.0% |
| FY Dec 2024 | -28.1% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -44.1% |
| Mar 2026 | -50.0% |
| Dec 2025 | -53.0% |
| Sep 2025 | -44.0% |
| Jun 2025 | -47.9% |
| Mar 2025 | -38.6% |
| Dec 2024 | -28.1% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital SLN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-56.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed SLN
| FY Dec 2025 | -60.0% |
| FY Dec 2024 | -44.8% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -56.0% |
| Mar 2026 | -57.9% |
| Dec 2025 | -60.0% |
| Sep 2025 | -64.1% |
| Jun 2025 | -57.6% |
| Mar 2025 | -51.9% |
| Dec 2024 | -44.8% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing SLN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value SLN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-1.5%
TTM free cash flow over market value at close 2026-10-26
FCF yield SLN
| FY Dec 2025 | -7.2% |
| FY Dec 2024 | -8.3% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -2.7% |
| Mar 2026 | -8.8% |
| Dec 2025 | -7.2% |
| Sep 2025 | -9.9% |
| Jun 2025 | -10.6% |
| Mar 2025 | -17.8% |
| Dec 2024 | -8.3% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing SLN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $559.0K | $43.3M | $31.6M | $21.7M |
| Gross profit | $344.0K | $31.4M | $18.8M | $8.2M |
| Operating income | -$91.1M | -$63.3M | -$64.4M | -$61.0M |
| Net income | -$88.6M | -$45.3M | -$54.2M | -$50.3M |
| EPS (diluted) | -0.63 | -0.33 | -0.49 | -0.52 |
| Operating cash flow | -$62.3M | -$67.6M | -$49.5M | -$57.0M |
| Cash | $11.3M | $121.3M | $68.8M | n/a |
SEC XBRL, fiscal years, as known on 2026-10-28
SLN Stock Sonar score 4/7 axes
Find similar shapesCompareSLN ranks highest on risk and compliance (45th percentile) and institutional and government (44th), and lowest on growth (9th), among Pharma & Biotech peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
